Mainstream chatbots presented varying levels of resistance to deliberate requests for fabrication, study finds ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now.

The Go for Bold initiative, which aims to help individuals in Washington County, Maryland, lose 1 million lb by 2030, serves as a successful, replicable model for community-wide health improvement. In ...

Healthtech and edtech are two of the fastest growing sectors, with the healthtech market size to reach $3.1 billion by 2033, while the global education technology market size is projected to reach ...

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and ...

OpenAI has launched GPT-5.4, its first model with native computer-use capabilities, alongside financial plugins for Microsoft Excel and Google Sheets.

Q4 2025 Earnings Call March 5, 2026 4:30 PM ESTCompany ParticipantsAllan Kells - Vice President of Investor RelationsSean Duffy ...

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.

Large language models are advancing rapidly, delivering AI agents and enabling the creation of lightweight, task-specific applications in days rather than months. Read more here.

The "nanoparticle" system sends genetic instructions via mRNA directly to the cells that produce insulin, blocking the body's immune system attack on insulin-producing beta cells in the pancreas.

Doctors warn that AI isn't perfect, but the info will likely be more personalized and specific than what patients might find through a Google search.